Exploring new frontiers for the pharmacological treatment of insomnia
Identificadores
URI: http://hdl.handle.net/20.500.12020/769ISSN: 2161-1459
DOI: 10.4172/2161-1459.1000e133
Fecha
2014-11-03Tipo de documento
articleÁrea/s de conocimiento
PsicologíaResumen
Insomnia is the most common sleep disorder and approximately
10% of the world’s population will report that they suffer from chronic
or persistent insomnia [1]. Insomnia is a condition of unsatisfactory
sleep, either in terms of sleep onset, sleep maintenance or early waking.
Furthermore, insomnia impairs daytime well-being and subjective
abilities and functioning. Insomnia must be considered a ‘24-hour’
disorder [2].
In contrast with DSM-IV, the new Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-V) does not
distinguish between primary insomnia and secondary insomnia.
DSM-V recognizes that co-existing medical or mental conditions with
sleep disorders (comorbid insomnia) are interactive and bidirectional.
For this reason, the diagnosis of primary insomnia has been renamed
insomnia disorder [3]. This change in the definition of insomnia will
most likely change the approach to insomnia drug development.